| Business Summary | | XOMA
Ltd.
is
a
biopharmaceutical
company
that
develops
and
manufactures
antibody
and
other
protein
products
to
treat
cancer,
immunological
and
inflammatory
disorders,
and
infectious
diseases.
The
Company's
current
product
development
programs
include:
Xanelim,
efalizumab
anti-CD11a;
ING-1,
a
Human
Engineered
recombinant
monoclonal
antibody;
Genimune,
a
Human
Engineered
recombinant
antibody
fusion
protein;
CI-1042,
a
therapeutic
tumor-selective,
modified
adenovirus;
NEUPREX
(rBPI21);
and
Mycoprex. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | XOMA
develops
and
manufactures
antibody
and
other
protein
biopharmaceuticals
for
disease
targets
that
include
immunological
and
inflammatory
disorders,
infectious
diseases
and
cancer.
For
the
three
months
ended
3/31/01,
revenues
rose
11%
to
$2.9
million.
Net
loss
increased
21%
to
$7.6
million.
Results
reflect
the
recognition
of
certain
license
and
other
fee
payments
received
from
Baxter
and
Onyx,
offset
by
increased
product
development
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
5,212;
after
tax
earnings
were
-6,648. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | John
L. Castello,
Chmn./Pres./CEO Peter
B. Davis,
VP-Fin./CFO Christopher
J. Margolin,
VP/Counsel/
Secy. Clarence
L. Dellio,
Sr. VP. | More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|